Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
NCT03744715 · Spectrum Pharmaceuticals, Inc · PHASE2 · terminated · last registry update 2026-07-28 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business reasons, not related to safety.” | – | Registry record, Spectrum Pharmaceuticals, Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ERBB2 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-03Also stopped (terminated): Petrov, Andrey, Afatinib Dimaleat + inhalation of afatinib dimaleate (NCT06897735)
- 2026-04-27Also stopped (terminated): Partner Therapeutics, Inc., Afatinib Oral Tablet + Enzalutamide Pill (NCT05588609)
- 2025-09-22Phase 3 first posted: ArriVent BioPharma, Inc., Firmonertinib + EGFR-TKI inhibitor based on investigator's choice (NCT07185997)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision